1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

European Physicians’ Biosimilar Views: A Primer

  • March 2014
  • 40 pages
  • Industry Standard Research
Report ID: 3095644

Summary

Table of Contents

In February 2014, Alvogen announced the launch of Inflectra (infliximab) into Central and Eastern Europe. Inflectra is a biosimilar medicine to the reference medicinal product, Remicade, and is the first monoclonal antibody to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. Remicade recorded European sales of over USD 2 billion in 2012.

So the biosimilar approvals are coming, but will physicians prescribe them? To find out, ISR asked 348 board-certified physicians across Spain, Italy, France, and Germany what they thought about prescribing biosimilar products.

What you will learn in this report:

- European physicians’ familiarity with biologic and biosimilar medicines
- Physician attitudes toward clinical development requirements for biosimilar medicines
- Physician views on pharmacy-level substitutions
- Importance of medication cost when prescribing
- Impact biosimilar pricing has on prescribing recommendations
- Physician concern with safety and efficacy of biosimilar products
- Current and future prescribing behavior for biosimilar medicines

Methodologies:
348 European physicians were surveyed for this report on the biosimilar landscape in France (N=87), Spain (N=87), Germany (N=87), and Italy (N=87).

To qualify to take this survey, physicians had to pass several screening criteria:

- Had to currently prescribe medications to patients
- Had to be board certified in one of the following therapeutic areas:

- Dermatology
- Endocrinology
- Gastrointestinal
- Hematology oncology
- Nephrology
- Neurology
- Oncology
- Rheumatology

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Biosimilars Market, Europe, Forecast to 2025

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

A Growing Number of Incentive Policies to Propel Growth in the Next 5–7 Years, with Oncology as the Fastest Adopter Patent expiration and increased use of traditional generic drugs are leading to a ...

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.